Modality
mRNA
MOA
CD47i
Target
CD38
Pathway
Angiogenesis
OCDUrothelial CaMDS
Development Pipeline
Preclinical
~May 2010
→ ~Aug 2011
Phase 1
~Nov 2011
→ ~Feb 2013
Phase 2
~May 2013
→ ~Aug 2014
Phase 3
~Nov 2014
→ ~Feb 2016
NDA/BLA
~May 2016
→ ~Aug 2017
Approved
Nov 2017
→ Feb 2029
ApprovedCurrent
NCT03395165
122 pts·MDS
2024-09→2026-12·Not yet recruiting
NCT04115934
2,127 pts·MDS
2020-11→2029-02·Terminated
NCT06510751
280 pts·OCD
2017-11→TBD·Not yet recruiting
+1 more trial
2,981 total pts2 indications
CompletedCurrentUpcoming
Catalysts (2)
2026-12-018mo awayPh3 Readout· MDS
2029-02-082.9y awayPh3 Readout· MDS
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Approved
Not yet…
Approved
Recruit…
Approved
Termina…
Approved
Not yet…
Catalysts
Ph3 Readout
2026-12-01 · 8mo away
MDS
Ph3 Readout
2029-02-08 · 2.9y away
MDS
RecruitingTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03395165 | Approved | MDS | Not yet recr... | 122 | MRD |
| NCT04115934 | Approved | MDS | Terminated | 2127 | EFS |
| NCT06510751 | Approved | OCD | Not yet recr... | 280 | EASI-75 |
| NCT05274113 | Approved | OCD | Recruiting | 452 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 |